Described herein are methods for selecting lymphocytes for adoptive cell therapy based on P-glycoprotein expression and compositions comprising same.

Methods of producing and manufacturing retroviral particles. Such methods may involve the use of an ion-exchange column with an elution buffer comprising one or more salts, wherein the elution buffer has a low total salt concentration (e.g., 400 mM to 800 mM) relative to conventional practice. In some embodiments, the retroviral particles can be generated by host cells transfected with retroviral vectors using polyethylenimine (PEI).

Systems and methods for sorting T cells are disclosed. Autofluorescence data is acquired from individual cells. An activation value is computed using one or more autofluorescence endpoints as an input. The one or more autofluorescence endpoints includes NAD(P)H shortest fluorescence lifetime amplitude component (α.sub.1).

Methods and compositions for promoting donor-specific tolerance and immunocompetence to a recipient of a solid organ transplant, by implanting an allogeneic solid organ in a recipient in need of a solid organ transplant and further comprising surgical implantation of a tissue-engineered allogeneic cultured postnatal thymus tissue product in the recipient of a solid organ from a donor.

The present invention is directed to the use of microfluidics in the preparation of cells and compositions for therapeutic uses.

Disclosed is a method for detecting regulatory dendritic cells, the method comprising step a: detecting the presence or absence of one or more types of molecules on a cell surface in a cell population that comprises regulatory dendritic cells; and step b: identifying regulatory dendritic cells on the basis of the presence or absence of the one or more types of molecules. Also disclosed is a method for producing a cell population enriched for regulatory dendritic cells, the method comprising step 1: detecting the presence or absence of one or more types of molecules on a cell surface in a cell population that comprises regulatory dendritic cells; and step 2: obtaining a cell population enriched for regulatory dendritic cells on the basis of the presence or absence of the one or more types of molecules. Further disclosed is a cell population enriched for regulatory dendritic cells obtained by the method.

A closed-system (i.e., hermetically sealed) methods, and kits for isolating Mesenchymal Stromal Cells (MSCs) from lipoaspirate, that utilizes specific hermetically-sealed, disposable assemblies and containers that are aseptically interconnected, are disclosed. Contemplated methods require lipoaspirate as a starting material, and provide for obtaining isolated, purified MSCs at the end of the process. Kits are contemplated to contain disposable assemblies, composed by sterile components such as modified syringes, tubing, centrifuge tubes, filtering units, that can be aseptically connected while maintaining sterility thereby keeping the system closed (i.e., hermetically sealed) with respect to the external environment. As a result, contamination during the isolation process can be avoided. The MSCs that are obtained at the end of the processing are thus ready to be further manipulated in subsequent operations (in example, expansion) also for therapeutic purposes.

A method of manufacturing of Natural Killer (NK) Cells genetically modified with lentiviral vectors carrying a polynucleotide coding for a Chimeric Antigen Receptors (CARs). CAR-NK cells obtained with the method, and the use of the CAR-NK cells in medicine, in particular for use in a method of treating cancer is also disclosed.

Disclosed is a method for treating or preventing GvHD in a transplant patient by administering to the patient autologous, ex vivo-modified and expanded CD4.sup.+CD25.sup.+Foxp3.sup.+CD127.sup.low T reg cells.

Methods for the ex vivo use of NAD to remove T cells that can potentially cause graft-verus-host disease (GvHD) from hematopoietic stem cell sources. Hematopoietic stem cell sources include bone marrow, cord blood, and peripheral blood (including mobilized peripheral blood). The present invention is a method including steps for using the hematopoietic stem cell sources treated with NAD for hematopoietic stem cell transplants (HSCTs). HSCTs are used as the standard-of-care in many diseases including several types of cancer and several genetic disorders. The majority of these transplants are allogeneic, in which the stem cell source comes from a donor who is a different individual than the intended recipient. Allogeneic HSCTs carry a risk of causing GvHD, in which donor T cells attack the recipient.